About us

Zealand Pharma A/S was founded in 1998 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a world leader in specialty medicines focusing on metabolic and gastrointestinal diseases. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and a pipeline of product candidates that primarily target significant unmet needs in metabolic and gastrointestinal diseases.

Marketed products

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin® in the U.S. and Lyxumia® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus®) and is marketed as Soliqua™ 100/33 in the U.S. and has been approved as Suliqua™ in Europe and launched in the Netherlands.

Lixisenatide is available as Adlyxin® in the US and is approved as Lyxumia® in more than 60 countries worldwide and marketed in over 40 by Sanofi. Commercial launches include most EU countries, Japan, Brazil, Mexico and India.

Soliqua™ 100/33 is a combination of lixisenatide and Lantus®
and is marketed by Sanofi in the U.S. The product is approved
as Suliqua™ in the EU. Suliqua will be delivered in two pre-filled
SoloSTAR® pens, providing different dosing options

Product pipeline

Zealand's pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand in brief

Product pipeline

• Glepaglutide* for short bowel syndrome (SBS)
• Dasiglucagon* for acute, severe hypoglycemia
• Dasiglucagon* for type 1 diabetes care
• Dasiglucagon for congenital hyperinsulinemia

• A dual GLP1-GLU for obesity/type 2 diabetes
• Amylin analogue for obesity/type 2 diabetes

Scientific focus and platform

We invent and develop medicines focusing on specialty metabolic and gastrointestinal diseases.

Zealand has a successful 18 year history of discovering and optimizing peptide therapeutics as novel drugs.